Relmada Therapeutics Inc SEC Filings

Relmada Therapeutics (RLMD) Form 4: An officer serving as CAO and COO reported an open-market purchase (transaction code P) of 136,000 shares of common stock on 11/05/2025 at $2.2 per share. Following the transaction, the reporting person beneficially owns 403,931 shares, held directly. The filing indicates a single reporting person and relates to Relmada Therapeutics, Inc.

Relmada Therapeutics (RLMD) insider activity: Chief Executive Officer and Director Sergio Traversa reported a purchase of 272,500 shares of Common Stock on 11/05/2025 at $2.2 per share (transaction code P).

Following the trade, he beneficially owns 1,272,500 shares, held directly. This Form 4 reflects an open-market or private purchase and updates his direct ownership position.

Relmada Therapeutics (RLMD) insider activity: Chief Operating Officer and Director Paul Kelly purchased 90,000 shares of common stock at $2.2 on 11/05/2025. Following the transaction, he directly beneficially owns 502,295 shares.

Relmada Therapeutics (RLMD) priced an underwritten equity offering of 40,142,000 common shares at $2.20 per share and pre-funded warrants to purchase up to 5,315,000 shares at $2.199 per warrant. The company expects approximately $100 million in net proceeds after underwriting discounts and expenses.

Pre-funded warrants are immediately exercisable at an exercise price of $0.001 per share, with a beneficial ownership cap of 9.99% (or 4.99% at the purchaser’s election). Company insiders, including the CEO, CFO, and other officers and directors, will purchase about $2.6 million of common stock at the same price as other investors.

Relmada plans to use proceeds for working capital and general corporate purposes, including clinical studies to gain regulatory approvals, further product development, licensing, and potential investments or acquisitions. The company agreed to customary indemnification provisions and 90-day restrictions on issuing additional equity or convertible securities.

Relmada Therapeutics (RLMD) launched a primary offering of 40,142,000 shares of common stock at $2.20 per share and pre-funded warrants for 5,315,000 shares, together with 5,315,000 shares issuable upon exercise of those pre-funded warrants. Gross proceeds are $100,000,085, with underwriting discounts of $6,000,324 and proceeds before expenses of $93,999,761; the company estimates net proceeds of approximately $93.7 million.

Relmada plans to use the funds for working capital and general corporate purposes, including clinical studies and development of product candidates. Pre-funded warrants are immediately exercisable at $0.001 per share, with an ownership cap of 9.99% (or 4.99% at the holder’s election). Certain officers indicated interest in up to about $2.6 million of shares at the offering price, which is non-binding. Shares outstanding would be 73,333,622 immediately after the offering, assuming no exercise of pre-funded warrants. As of October 24, 2025, shares outstanding were 33,191,622.

Relmada Therapeutics (RLMD) reported FDA feedback on its proposed Phase III program for NDV-01 in non-muscle invasive bladder cancer and shared nine-month Phase II safety and efficacy data. The FDA indicated a single-arm trial may be acceptable in BCG‑unresponsive patients refractory to other therapies, and a randomized post‑TURBT adjuvant study versus observation in intermediate‑risk NMIBC with a time‑to‑event primary endpoint is generally acceptable, subject to submission of the intended designs. The company plans to request Type B meetings.

In Phase II high‑risk NMIBC, NDV‑01 showed no Grade ≥3 treatment‑related adverse events among 36 patients; 61% had treatment‑related adverse events, primarily transient dysuria (62%), asymptomatic positive urine culture (9%), and hematuria (7%). Complete response rates were 92% (anytime; 23/25), 84% at 3 months (21/25), 87% at 6 months (20/23), and 85% at 9 months (17/20), with two of two patients in CR at 12 months. Relmada expects approximately $13.9 million in cash, cash equivalents and short‑term investments as of September 30, 2025.